Cargando…
Surgery followed by concurrent radiochemotherapy as treatment for patients with locally recurrent cervical cancer
BACKGROUND: No standard treatment exists for patients with recurrent cervical cancer. This study aimed to determine the role of surgery, followed by concurrent radiochemotherapy, as a treatment for recurrent pelvic cervical cancer without previous radiotherapy. METHODS: The current study identified...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797628/ https://www.ncbi.nlm.nih.gov/pubmed/35116295 http://dx.doi.org/10.21037/tcr-21-1163 |
_version_ | 1784641597304995840 |
---|---|
author | Zhang, Xiang Chen, Zhongbo Chen, Jianhong Wang, Junjian Wang, Yingchang Zhu, Jianqing |
author_facet | Zhang, Xiang Chen, Zhongbo Chen, Jianhong Wang, Junjian Wang, Yingchang Zhu, Jianqing |
author_sort | Zhang, Xiang |
collection | PubMed |
description | BACKGROUND: No standard treatment exists for patients with recurrent cervical cancer. This study aimed to determine the role of surgery, followed by concurrent radiochemotherapy, as a treatment for recurrent pelvic cervical cancer without previous radiotherapy. METHODS: The current study identified patients diagnosed with vaginal and/or pelvic sidewall recurrent cervical cancer after primary surgery without radiotherapy in Zhejiang Cancer Hospital from May 2012 to November 2016. These enrolled patients underwent surgery, followed by concurrent radiochemotherapy and data were analyzed. RESULTS: This study enrolled 27 patients, including 11 with central (vaginal) and 16 with noncentral (pelvic sidewall with or without vaginal) recurrences. The median follow-up time after recurrence was 64 months (range, 5–110 months). All patients underwent surgery to resect the tumor as completely as possible and pelvic external beam radiotherapy (EBRT) with a median equivalent dose in 2 Gy fractions (EQD2) of 45.1 Gy (range, 44.3–47.8 Gy) with concurrent weekly cisplatin chemotherapy. The median EQD2 dose for the tumor bed/residual tumor was 51 Gy (range, 44.3–73.4 Gy), including 18 patients with a boost dose by EBRT or vaginal brachytherapy (VBT). The 5-year overall survival (OS) rates were 77.1% (central) and 65.7% (noncentral) without a statistically significant difference (P=0.246). Progression-free survival (PFS) rates were 81.8% (central) and 34.4% (noncentral), respectively, with a statistically significant difference (P=0.047). Three patients with noncentral recurrence experienced grade ≥3 complications associated with surgery. CONCLUSIONS: Surgery followed by concurrent radiochemotherapy was a feasible and effective treatment with acceptable complications for locally recurrent cervical cancer, which markedly improved the survival of pelvic sidewall recurrence. |
format | Online Article Text |
id | pubmed-8797628 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-87976282022-02-02 Surgery followed by concurrent radiochemotherapy as treatment for patients with locally recurrent cervical cancer Zhang, Xiang Chen, Zhongbo Chen, Jianhong Wang, Junjian Wang, Yingchang Zhu, Jianqing Transl Cancer Res Original Article BACKGROUND: No standard treatment exists for patients with recurrent cervical cancer. This study aimed to determine the role of surgery, followed by concurrent radiochemotherapy, as a treatment for recurrent pelvic cervical cancer without previous radiotherapy. METHODS: The current study identified patients diagnosed with vaginal and/or pelvic sidewall recurrent cervical cancer after primary surgery without radiotherapy in Zhejiang Cancer Hospital from May 2012 to November 2016. These enrolled patients underwent surgery, followed by concurrent radiochemotherapy and data were analyzed. RESULTS: This study enrolled 27 patients, including 11 with central (vaginal) and 16 with noncentral (pelvic sidewall with or without vaginal) recurrences. The median follow-up time after recurrence was 64 months (range, 5–110 months). All patients underwent surgery to resect the tumor as completely as possible and pelvic external beam radiotherapy (EBRT) with a median equivalent dose in 2 Gy fractions (EQD2) of 45.1 Gy (range, 44.3–47.8 Gy) with concurrent weekly cisplatin chemotherapy. The median EQD2 dose for the tumor bed/residual tumor was 51 Gy (range, 44.3–73.4 Gy), including 18 patients with a boost dose by EBRT or vaginal brachytherapy (VBT). The 5-year overall survival (OS) rates were 77.1% (central) and 65.7% (noncentral) without a statistically significant difference (P=0.246). Progression-free survival (PFS) rates were 81.8% (central) and 34.4% (noncentral), respectively, with a statistically significant difference (P=0.047). Three patients with noncentral recurrence experienced grade ≥3 complications associated with surgery. CONCLUSIONS: Surgery followed by concurrent radiochemotherapy was a feasible and effective treatment with acceptable complications for locally recurrent cervical cancer, which markedly improved the survival of pelvic sidewall recurrence. AME Publishing Company 2021-10 /pmc/articles/PMC8797628/ /pubmed/35116295 http://dx.doi.org/10.21037/tcr-21-1163 Text en 2021 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/. |
spellingShingle | Original Article Zhang, Xiang Chen, Zhongbo Chen, Jianhong Wang, Junjian Wang, Yingchang Zhu, Jianqing Surgery followed by concurrent radiochemotherapy as treatment for patients with locally recurrent cervical cancer |
title | Surgery followed by concurrent radiochemotherapy as treatment for patients with locally recurrent cervical cancer |
title_full | Surgery followed by concurrent radiochemotherapy as treatment for patients with locally recurrent cervical cancer |
title_fullStr | Surgery followed by concurrent radiochemotherapy as treatment for patients with locally recurrent cervical cancer |
title_full_unstemmed | Surgery followed by concurrent radiochemotherapy as treatment for patients with locally recurrent cervical cancer |
title_short | Surgery followed by concurrent radiochemotherapy as treatment for patients with locally recurrent cervical cancer |
title_sort | surgery followed by concurrent radiochemotherapy as treatment for patients with locally recurrent cervical cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797628/ https://www.ncbi.nlm.nih.gov/pubmed/35116295 http://dx.doi.org/10.21037/tcr-21-1163 |
work_keys_str_mv | AT zhangxiang surgeryfollowedbyconcurrentradiochemotherapyastreatmentforpatientswithlocallyrecurrentcervicalcancer AT chenzhongbo surgeryfollowedbyconcurrentradiochemotherapyastreatmentforpatientswithlocallyrecurrentcervicalcancer AT chenjianhong surgeryfollowedbyconcurrentradiochemotherapyastreatmentforpatientswithlocallyrecurrentcervicalcancer AT wangjunjian surgeryfollowedbyconcurrentradiochemotherapyastreatmentforpatientswithlocallyrecurrentcervicalcancer AT wangyingchang surgeryfollowedbyconcurrentradiochemotherapyastreatmentforpatientswithlocallyrecurrentcervicalcancer AT zhujianqing surgeryfollowedbyconcurrentradiochemotherapyastreatmentforpatientswithlocallyrecurrentcervicalcancer |